Published in Virology on September 15, 1996
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol (2002) 2.53
Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol (1998) 2.09
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A (2002) 2.04
Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol (1999) 1.93
Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol (2001) 1.90
Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol (2007) 1.61
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
Evidence for separation of HCV subtype 1a into two distinct clades. J Viral Hepat (2010) 1.26
High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol (2004) 1.25
Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. J Virol (2000) 1.18
Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol (2001) 1.17
Temporal variations in the hepatitis C virus intrahost population during chronic infection. J Virol (2011) 1.15
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol (2000) 1.14
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection. J Virol (1998) 1.09
Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol (2002) 1.06
Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03
Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol (2001) 1.02
Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol (2014) 0.99
Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J Virol (2000) 0.96
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J (2008) 0.95
Production and characterization of monoclonal antibodies specific for a conserved epitope within hepatitis C virus hypervariable region 1. J Virol (2001) 0.94
Protective immunity against hepatitis C: many shades of gray. Front Immunol (2014) 0.94
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol (2001) 0.92
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C. Virology (2008) 0.89
Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol (1999) 0.89
Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. World J Gastroenterol (2006) 0.88
Progress towards a hepatitis C virus vaccine. Emerg Microbes Infect (2013) 0.87
Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles. J Viral Hepat (2009) 0.85
Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine. J Clin Immunol (2005) 0.84
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
Reproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species. J Virol (2011) 0.80
Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep (2015) 0.80
Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79
Replication of GB virus C (hepatitis G virus) in interferon-resistant Daudi cells. J Virol (1999) 0.79
Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models. World J Gastroenterol (2006) 0.78
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol (2015) 0.78
Expression of hepatitis C virus hypervariable region 1 and its clinical significance. World J Gastroenterol (2003) 0.75
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
DNA polymerase associated with human hepatitis B antigen. J Virol (1973) 10.71
Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci U S A (1990) 8.92
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
A colour test for the measurement of antibody to certain mycoplasma species based upon the inhibition of acid production. J Hyg (Lond) (1966) 6.23
Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A (1997) 6.09
A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci U S A (1997) 6.07
Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med (1966) 5.97
Color test for the measurement of antibody to T-strain mycoplasmas. J Bacteriol (1966) 5.61
Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis (1995) 5.53
Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A (1991) 5.51
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
An African primate lentivirus (SIVsm) closely related to HIV-2. Nature (1989) 5.03
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med (1991) 4.79
A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species. Proc Natl Acad Sci U S A (2001) 4.62
Complete nucleotide sequence of wild-type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol (1987) 4.49
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology (1990) 4.43
Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis (1980) 4.28
Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med (1991) 4.24
Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis (1981) 4.15
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology (1999) 4.04
Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol (2002) 3.83
Genetic and experimental evidence for cross-species infection by swine hepatitis E virus. J Virol (1998) 3.73
Sequence analysis of the 5' noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A (1992) 3.72
Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1989) 3.67
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A (1994) 3.56
Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci U S A (1992) 3.55
A microtiter solid-phase radioimmunoassay for hepatitis A antigen and antibody. J Immunol (1976) 3.53
At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci U S A (1993) 3.37
Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med (1975) 3.31
Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet (1980) 3.31
Australia antigen: large-scale purification from human serum and biochemical studies of its proteins. J Virol (1971) 3.28
Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage. Infect Immun (1981) 3.18
Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol (1994) 3.06
ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J Infect Dis (1993) 3.06
Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03
A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature (1983) 3.02
Frequency of antibody to hepatitis-associated antigen as measured by a new radioimmunoassay technique. J Immunol (1971) 2.98
Microtiter solid-phase radioimmunoassay for hepatitis B antigen. Appl Microbiol (1973) 2.96
Molecular cloning and characterization of hepatitis A virus cDNA. Proc Natl Acad Sci U S A (1983) 2.92
Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck. Proc Natl Acad Sci U S A (1984) 2.87
The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol (1993) 2.84
Hepatitis A virus cDNA and its RNA transcripts are infectious in cell culture. J Virol (1987) 2.83
Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A (1994) 2.83
Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun (1984) 2.81
A color test for the measurement of antibody to the non-acid-forming human Mycoplasma species. Am J Epidemiol (1966) 2.81
Transmissible agent in non-A, non-B hepatitis. Lancet (1978) 2.78
Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science (1979) 2.78
Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology (1998) 2.76
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 2.73
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Compact organization of the hepatitis B virus genome. Hepatology (1989) 2.70
Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis (1987) 2.68
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med (1976) 2.67
Characterization of a prototype strain of hepatitis E virus. Proc Natl Acad Sci U S A (1992) 2.64
Enzyme-linked immunosorbent assay for detection of hepatitis A antigen in stool and antibody to hepatitis A antigen in sera: comparison with solid-phase radioimmunoassay, immune electron microscopy, and immune adherence hemagglutination assay. J Clin Microbiol (1978) 2.64
Age-specific prevalence of antibodies to hepatitis A and E viruses in Pune, India, 1982 and 1992. J Infect Dis (1995) 2.63
A complement-fixation test for measuring Australia antigen and antibody. J Infect Dis (1969) 2.58
In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci U S A (1999) 2.56
Complete nucleotide sequence of an attenuated hepatitis A virus: comparison with wild-type virus. Proc Natl Acad Sci U S A (1987) 2.56
Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med (1994) 2.55
Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol (1997) 2.48
Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. Proc Natl Acad Sci U S A (1987) 2.46
Biophysical properties of Australia antigen. J Virol (1969) 2.45
Hepatitis C virus: detection of intracellular virus particles by electron microscopy. Hepatology (1996) 2.44
Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis (1975) 2.41
Clinical and serological analysis of transfusion-associated hepatitis. Lancet (1975) 2.41
Hepatitis B and hepatitis C in emergency department patients. N Engl J Med (1992) 2.39
Comparative pathogenesis of infection of pigs with hepatitis E viruses recovered from a pig and a human. J Clin Microbiol (2001) 2.38
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1992) 2.30
Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet (1979) 2.29
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
Purification of hepatitis A antigen from feces and detection of antigen and antibody by immune adherence hemagglutination. Infect Immun (1976) 2.27
Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol (1991) 2.27
Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med (1986) 2.27
A microtiter solid phase radioimmunoassay for detection of the human reovirus-like agent in stools. J Immunol (1977) 2.24
Experimental infection of pigs with the newly identified swine hepatitis E virus (swine HEV), but not with human strains of HEV. Arch Virol (1998) 2.24
Hepatitis A virus infection: new insights from seroepidemiologic studies. J Infect Dis (1978) 2.21
Nucleotide sequence analysis of feline immunodeficiency virus: genome organization and relationship to other lentiviruses. Proc Natl Acad Sci U S A (1989) 2.21
Nucleotide sequence of the staphylocoagulase gene: its unique COOH-terminal 8 tandem repeats. J Biochem (1987) 2.21
Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet (1980) 2.17
Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med (1983) 2.16
Demonstration of subpopulations of Dane particles. J Virol (1976) 2.14
Identification of a family of streptococcal surface proteins with extremely repetitive structure. J Biol Chem (1996) 2.09
Determination and analysis of the complete genomic sequence of avian hepatitis E virus (avian HEV) and attempts to infect rhesus monkeys with avian HEV. J Gen Virol (2004) 2.09
Evidence for widespread infection of wild rats with hepatitis E virus in the United States. Am J Trop Med Hyg (1999) 2.08
Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology (1998) 2.06
A comparison of the frequency of hepatitis-B antigen and antibody in hospital and nonhospital personnel. N Engl J Med (1973) 2.05
Early events in hepatitis C virus infection of chimpanzees. Proc Natl Acad Sci U S A (1990) 2.04
Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut (2005) 2.03